List of Excipients in Branded Drug FREAMINE HBC

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	FREAMINE HBC	isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, glycine, cysteine, and sodium bisulfite	0264-9350	SODIUM BISULFITE
B Braun Medical Inc	FREAMINE HBC	isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, glycine, cysteine, and sodium bisulfite	0264-9350	WATER

Freamine HBC Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: October 29, 2026

Freamine HBC is an amino acid injection used as a component of parenteral nutrition, particularly where a concentrated branched-chain amino acid profile is clinically relevant. Its commercial opportunity is driven by sterile manufacturing, supply reliability, pharmacy workflow, container systems and clinical nutrition protocols rather than by a surviving small-molecule patent estate. The most defensible product improvements are ready-to-use presentations, improved container compatibility, reduced compounding burden and differentiated nutrition formulations.

What is Freamine HBC and how is it used?

Freamine HBC is a sterile amino acid solution for intravenous administration as part of parenteral nutrition. The formulation contains essential and nonessential amino acids, with a relatively high proportion of branched-chain amino acids. It is administered with dextrose, lipid emulsion, electrolytes, vitamins and trace elements selected according to patient requirements.

The product is not a complete parenteral nutrition regimen by itself. Amino acid injections generally require individualized admixture and clinical monitoring of nitrogen balance, fluid status, electrolytes, glucose, renal function and hepatic function. Product labeling directs use under the supervision of clinicians experienced in intravenous nutritional therapy.[1]

Core product attributes

Attribute	Freamine HBC assessment
Dosage form	Sterile intravenous amino acid solution
Therapeutic category	Parenteral nutrition
Active nutritional components	Essential and nonessential amino acids
Differentiating composition	High branched-chain amino acid content
Primary users	Hospitals, intensive-care units, specialty pharmacies and home-infusion providers
Administration	Intravenous infusion, generally after compounding with other nutrition components
Regulatory category	Prescription parenteral product
Primary commercial barrier	Sterile manufacturing and compatibility validation
Main substitution risk	Other amino acid injections and commercially prepared parenteral nutrition bags

Freamine HBC should be evaluated as a formulation and supply-chain product, not as a conventional branded drug with substantial residual active-ingredient exclusivity.

What excipients are used in Freamine HBC?

The principal excipient platform is water for injection with pH adjustment. Amino acid injections are aqueous sterile solutions, and the formulation must preserve amino acid stability, acceptable osmolarity, container compatibility and microbiological quality.

Public product information identifies the formulation as an amino acid injection with water for injection and pH-adjusting components. Exact quantitative excipient composition should be taken from the controlling package insert and current regulatory file because formulations and presentations can vary by manufacturer, concentration and market.[1]

Excipient functions

Excipient or formulation element	Function	Strategic relevance
Water for injection	Vehicle	Controls solubility, sterility and fill volume
Acetic acid or another permitted acidifying agent	pH adjustment	Influences amino acid stability and infusion tolerability
Amino acid blend	Nutritional active components	Determines nitrogen delivery, metabolic profile and clinical positioning
Container closure system	Product protection	Controls oxygen, extractables, leachables and shelf life
Overwrap or oxygen barrier	Protection during storage	Relevant for oxidation-sensitive formulations and commercial shelf life

The formulation strategy should avoid unnecessary excipients. A low-excipient profile reduces compatibility risks and simplifies hospital pharmacy review. The main technical risks are precipitation, pH drift, oxidation, Maillard-type reactions after admixture with dextrose, sorption to plastic materials and instability after addition of electrolytes or trace elements.

What formulation patents protect Freamine HBC?

No commercially important, currently enforceable formulation patent estate is apparent from the age and nature of the Freamine HBC product. The product is based on established amino acid parenteral nutrition technology. Any original patents covering the amino acid composition, formulation concept or use would generally be expected to have expired after decades of commercial availability.

The relevant protection is more likely to arise from:

• Manufacturing process know-how.
• Sterile filtration and aseptic filling parameters.
• Amino acid dissolution sequence.
• Oxygen-control procedures.
• Container and closure selection.
• Admixture compatibility data.
• Shelf-life studies.
• Trade dress and trademark rights.
• Regulatory exclusivity, if any current jurisdiction-specific period remains.

A freedom-to-operate review should distinguish Freamine HBC as a trademarked product from patents covering amino acid solutions generally. A competitor normally would not need to copy the Freamine HBC trade name, labeling language, packaging design or proprietary manufacturing documentation to commercialize a competing amino acid injection.

When does Freamine HBC lose exclusivity?

Freamine HBC is unlikely to have a meaningful remaining exclusivity period based on the original product concept. Its commercial position depends on market authorization, manufacturing status, supply continuity and hospital purchasing contracts.

Exclusivity assessment

Exclusivity category	Freamine HBC position
New chemical entity exclusivity	Not applicable to an established amino acid mixture
Orphan-drug exclusivity	No apparent basis from the product’s general parenteral nutrition use
Pediatric exclusivity	No product-specific basis apparent
Reference-product exclusivity	Potentially relevant only if a current regulatory pathway treats the product as a reference product
Orange Book patent exclusivity	No material active patent position apparent from the legacy product profile
Trademark exclusivity	Potentially active, depending on registration and jurisdiction
Manufacturing exclusivity	May exist commercially through validated facilities and contracts, but is not the same as patent exclusivity

The practical entry question is whether a competitor can obtain approval for an equivalent amino acid injection and establish reliable sterile supply. That question is more important than the expiration date of an old formulation patent.

What is the FDA regulatory status and Orange Book position?

Freamine HBC is regulated as a prescription sterile parenteral product. The applicable FDA record must be checked by product name, concentration, application number, National Drug Code and marketing status because legacy nutrition products may appear under discontinued, archived or successor listings.

The Orange Book does not provide the complete commercial picture for parenteral nutrition products. Even where a product is listed, Orange Book status does not capture:

• Hospital purchasing contracts.
• Drug-shortage dynamics.
• Institutional compounding capacity.
• Pharmacy workflow preferences.
• Container compatibility.
• Admixture stability.
• Supply-chain qualification.
• State-level purchasing requirements.

For a competitive launch, the regulatory strategy would usually focus on demonstrating pharmaceutical equivalence, sterility, composition, concentration, stability and container compatibility. The specific FDA pathway depends on the reference listing and current product classification.[2]

What excipient strategy creates commercial opportunities?

The strongest opportunity is to convert a basic amino acid solution into a lower-friction nutrition product. Hospitals increasingly value products that reduce compounding steps, limit manipulation and support predictable pharmacy operations.

1. Ready-to-use and pharmacy-ready presentations

A manufacturer could offer Freamine HBC-equivalent amino acid solution in:

• Small-volume bags for individualized admixture.
• Larger bags designed for automated compounding.
• Clearly differentiated concentrations for adult and specialty use.
• Barcoded containers compatible with pharmacy automation.
• Packaging optimized for compounding devices.

The commercial value is operational. A product that reduces preparation time and error opportunities can compete even without a novel clinical claim.

2. Improved container systems

Container development is a defensible area because amino acid solutions must remain stable through storage, shipping and handling. Opportunities include:

• Low-oxygen multilayer bags.
• Improved ports for repeated pharmacy manipulation.
• Reduced extractables and leachables.
• Better overwrap protection.
• Clearer fill-volume markings.
• Packaging compatible with automated compounders.

A container innovation may support a patent application if it provides a specific, non-obvious solution to oxygen transmission, port integrity, admixture handling or stability.

3. Extended post-compounding stability

Hospitals need reliable beyond-use periods after amino acid solutions are combined with dextrose, lipid emulsions, electrolytes, vitamins and trace elements. A sponsor could generate a compatibility matrix covering:

• Common dextrose concentrations.
• Standard electrolyte combinations.
• Calcium and phosphate levels.
• Trace-element products.
• Multivitamin preparations.
• Automated compounding conditions.
• Refrigerated and room-temperature storage.

The resulting data can support labeling, pharmacy protocols and procurement decisions. The data package may be commercially valuable even if it does not create broad patent protection.

4. Preservative-free and low-additive positioning

Parenteral nutrition products generally benefit from a simple formulation. A preservative-free, low-excipient presentation can reduce pharmacy concerns about compatibility and patient exposure. The value depends on validated stability and a clear label, not merely on the absence of additives.

5. Specialized amino acid profiles

A new amino acid composition could create a stronger product position than a direct Freamine HBC copy. Possible directions include:

• Higher branched-chain amino acid content.
• Adjusted aromatic-to-branched-chain amino acid ratio.
• Renal nutrition profiles.
• Hepatic nutrition profiles.
• Pediatric or neonatal amino acid compositions.
• Lower total nitrogen formulations for selected patient groups.

A differentiated composition would require clinical and regulatory support. It could also face a higher evidence burden and more complex reimbursement review.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barrier is sterile quality. A competitor must demonstrate control of:

1. Raw-material identity and purity.
2. Amino acid assay and impurity profile.
3. Solution pH and osmolarity.
4. Bioburden and endotoxin.
5. Sterility assurance.
6. Filter compatibility.
7. Container closure integrity.
8. Particulate control.
9. Stability under labeled storage conditions.
10. Shipping and temperature excursions.

Amino acid solutions can appear simple but require rigorous control of dissolution sequence and solution exposure to heat, oxygen and light. Manufacturing know-how may reduce batch failures and improve yield, creating a practical advantage that is difficult to identify through a patent search.

Potential patentable areas

Development area	Patent potential
New amino acid ratio	Moderate, if technically and clinically differentiated
Novel pH or stabilizer system	Moderate, subject to prior-art review
Oxygen-control packaging	Moderate to strong if technically specific
Admixture compatibility method	Moderate, often narrow
Automated compounding workflow	Moderate, but may face software and obviousness issues
Sterile filling process	Usually better protected as know-how than broad patent claims
New indication for standard amino acid solution	Generally weak without clinical evidence
Trade name and packaging	Trademark and trade-dress protection, not patent protection

Which companies challenge or compete with Freamine HBC?

Competition comes from manufacturers of amino acid injections and complete parenteral nutrition products rather than from a single direct substitute. Relevant competitive groups include:

• Baxter, through amino acid and parenteral nutrition products.
• B. Braun, through amino acid solutions and nutrition systems.
• Fresenius Kabi, through amino acid injections, compounded nutrition and clinical nutrition products.
• ICU Medical, through nutrition-related infusion and compounding products.
• Regional sterile compounding pharmacies.
• Hospital pharmacies with compounding capacity.

The main competing products may differ in amino acid concentration, electrolyte content, container size and intended use. A direct comparison should be performed on concentration, nitrogen content, branched-chain amino acid percentage, container format, stability and current marketing status rather than brand name alone.

What generic entry risks exist?

Generic or alternative-product entry is technically feasible. The principal risks for an incumbent are:

• Approval of a therapeutically equivalent amino acid injection.
• Hospital conversion to a lower-cost supplier.
• Contract manufacturing by a large sterile-injectables company.
• Drug-shortage-driven substitution.
• Private-label nutrition products.
• Institutional pharmacy compounding.
• Substitution by complete parenteral nutrition products.

The incumbent’s strongest defenses are supply reliability, validated compatibility data, broad distribution, pharmacy familiarity and contractual status. Patent litigation is unlikely to be the central defense unless a newer container, composition or delivery system has been separately patented.

What patent litigation or Paragraph IV activity affects Freamine HBC?

No major, publicly recognized Paragraph IV or patent-litigation pattern is associated with the legacy Freamine HBC product profile. Paragraph IV litigation is more common for small-molecule drugs with active Orange Book patents. For an established amino acid injection, disputes are more likely to involve:

• ANDA approval timing.
• Product classification.
• Pharmaceutical equivalence.
• Sterility or manufacturing deficiencies.
• Trademark infringement.
• Contract disputes.
• Drug-shortage allocation.
• False or misleading comparative marketing.

A competitor’s regulatory challenge would likely have greater commercial impact than a conventional patent challenge because the product’s differentiation is primarily operational and formulation-based.

How does Freamine HBC compare with newer parenteral nutrition opportunities?

Commercial factor	Freamine HBC-type product	Newer nutrition platform
Clinical differentiation	Limited unless composition is specialized	Potentially higher
Patent strength	Low for legacy formulation	Moderate to strong if composition or packaging is novel
Regulatory complexity	Established product category	Higher if new clinical claims are pursued
Manufacturing complexity	High sterile manufacturing burden	High, with added development requirements
Hospital adoption	Familiarity can help	Requires formulary and protocol adoption
Pricing power	Generally limited	Higher if workflow or clinical outcome benefits are demonstrated
Generic risk	High	Lower while claims remain differentiated
Best commercial strategy	Reliable supply and workflow efficiency	Evidence-backed formulation or delivery innovation

What commercial opportunity is most attractive?

The most practical opportunity is a pharmacy-optimized amino acid injection with a validated compatibility package and reliable supply. A sponsor can combine:

• A familiar amino acid profile.
• A robust low-excipient formulation.
• A low-oxygen container.
• Multiple bag sizes.
• Automated-compounding compatibility.
• Digital barcode and inventory support.
• Published admixture stability data.
• Contractual supply guarantees.

A novel amino acid composition may generate higher intellectual-property value, but it also requires greater clinical development and carries more regulatory risk. The return profile is therefore better for a workflow-focused product unless the sponsor has a clear patient-population advantage.

What is the revenue exposure and launch scenario?

Revenue depends on institutional volume, contract pricing, manufacturing cost and shortage conditions. A direct substitute would usually face price pressure. A differentiated product can command stronger pricing if it reduces pharmacy labor, lowers waste or improves supply continuity.

Launch scenarios

Scenario	Commercial outcome
Direct equivalent	Rapid price competition and limited margin
Supply-reliable alternative	Share gains during shortages or incumbent disruption
Pharmacy-optimized bag system	Moderate premium if labor and error reduction are demonstrated
Specialized hepatic or renal formulation	Higher pricing, narrower market and greater evidence burden
Complete ready-to-use nutrition system	Larger value proposition but materially higher development complexity

Key Takeaways

• Freamine HBC is an established sterile amino acid injection used in parenteral nutrition.
• Its commercial value is based more on supply, formulation quality and pharmacy workflow than on active patent exclusivity.
• The principal formulation platform is water for injection, amino acids and pH adjustment, with container performance playing a major role.
• No material surviving patent estate is apparent for the legacy product concept.
• Orange Book status alone does not determine competitive risk in parenteral nutrition.
• The strongest opportunities are ready-to-use formats, improved containers, compatibility data and reliable sterile supply.
• Specialized amino acid profiles may create stronger patent positions but require greater clinical and regulatory investment.
• Paragraph IV litigation and conventional patent disputes are less likely to determine market access than manufacturing qualification, regulatory approval and hospital contracting.

FAQs

Is Freamine HBC a complete parenteral nutrition product?

No. It is an amino acid component that is generally combined with dextrose, lipid emulsion, electrolytes, vitamins and trace elements according to patient requirements.

Can Freamine HBC be replaced by another amino acid injection?

Potentially, subject to concentration, amino acid composition, clinical indication, regulatory status, pharmacy protocol and compatibility requirements. Substitution should not be treated as automatic brand interchangeability.

Is Freamine HBC protected by an active composition patent?

No material active composition patent is apparent for the legacy product concept. Current protection is more likely to involve trademarks, regulatory records, manufacturing know-how and newer packaging or formulation improvements.

What is the best patent strategy for a Freamine HBC competitor?

The strongest targets are differentiated amino acid ratios, validated stability systems, oxygen-control packaging, specialized patient populations and pharmacy-compatible delivery formats.

What is the main barrier to launching a competing product?

Sterile manufacturing qualification is the main barrier. A sponsor must also establish formulation stability, container closure integrity, particulate control, regulatory equivalence and dependable commercial supply.

References

1. DailyMed. (n.d.). Freamine HBC amino acid injection, solution: Product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. U.S. Food and Drug Administration. (2014). Guidance for industry: Drug products or biologics distributed with a change in container closure system. https://www.fda.gov/
4. U.S. Pharmacopeial Convention. (2023). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeia.
5. U.S. Food and Drug Administration. (2023). Parenteral nutrition products: Regulatory and quality considerations. https://www.fda.gov/